MX2011007371A - Metodo para tratar la hiperglucemia con la molecula. - Google Patents
Metodo para tratar la hiperglucemia con la molecula.Info
- Publication number
- MX2011007371A MX2011007371A MX2011007371A MX2011007371A MX2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- treating hyperglycemia
- diabetes
- diketopiperazine
- administered
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 201000001421 hyperglycemia Diseases 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona un método para tratar la hiperglucemia y/o diabetes en un sujeto. En particular, el método está dirigido a un tratamiento de pacientes con diabetes melitus tipo 2 quienes tienen una concentración de glucosa en la sangre en ayunas mayor de aproximadamente 8 mM, en donde el paciente es administrado con una formulación que comprende una molécula GLP-1 y una dicetopiperazina mediante inhalación pulmonar con un sistema de inhalación de polvo seco.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14335809P | 2009-01-08 | 2009-01-08 | |
| PCT/US2010/020448 WO2010080964A1 (en) | 2009-01-08 | 2010-01-08 | Method for treating hyperglycemia with glp-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011007371A true MX2011007371A (es) | 2011-09-06 |
Family
ID=41820660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011007371A MX2011007371A (es) | 2009-01-08 | 2010-01-08 | Metodo para tratar la hiperglucemia con la molecula. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9078866B2 (es) |
| EP (2) | EP2379100B1 (es) |
| JP (2) | JP5918539B2 (es) |
| AU (2) | AU2010203573A1 (es) |
| CA (1) | CA2749099A1 (es) |
| DK (1) | DK2379100T3 (es) |
| ES (1) | ES2529100T3 (es) |
| MX (1) | MX2011007371A (es) |
| PT (1) | PT2379100E (es) |
| SI (1) | SI2379100T1 (es) |
| WO (1) | WO2010080964A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4713798B2 (ja) | 1999-06-29 | 2011-06-29 | マンカインド コーポレイション | ペプチドおよびタンパク質の薬学的因子の精製および安定化 |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| SI1494732T1 (sl) | 2002-03-20 | 2008-08-31 | Mannking Corp | Inhalacijski aparat |
| AU2005277208B2 (en) | 2004-08-20 | 2011-11-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
| DK1791542T3 (en) | 2004-08-23 | 2015-06-15 | Mannkind Corp | Diketopiperazinsalte for pharmaceutical delivery |
| KR101486397B1 (ko) | 2005-09-14 | 2015-01-28 | 맨카인드 코포레이션 | 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법 |
| AU2007216966C1 (en) | 2006-02-22 | 2014-03-20 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
| KR101736535B1 (ko) * | 2007-10-24 | 2017-05-16 | 맨카인드 코포레이션 | Ｇｌｐ-1에 의한 유해 효과의 예방 방법 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| CN109568740B (zh) | 2008-06-13 | 2022-05-27 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| BRPI0914308B8 (pt) | 2008-06-20 | 2021-06-22 | Mannkind Corp | sistema de inalação |
| TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| EP2405963B1 (en) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| MY186975A (en) | 2009-06-12 | 2021-08-26 | Mannkind Corp | Diketopiperazine microparticles with defined specific surface areas |
| EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
| IL223742A (en) | 2010-06-21 | 2016-06-30 | Mannkind Corp | A dry powder inhaler and preparation for it |
| DK2694402T3 (en) | 2011-04-01 | 2017-07-03 | Mannkind Corp | BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| HK1201475A1 (en) | 2011-10-24 | 2015-09-04 | Mannkind Corporation | Methods and compositions for treating pain |
| SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
| AU2013308693A1 (en) * | 2012-08-29 | 2015-03-12 | Mannkind Corporation | Method and composition for treating hyperglycemia |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| ES2754388T3 (es) | 2013-03-15 | 2020-04-17 | Mannkind Corp | Composiciones y métodos de dicetopiperazina microcristalina |
| EP3021834A1 (en) | 2013-07-18 | 2016-05-25 | MannKind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| JP2016530930A (ja) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | 通気装置及び方法 |
| WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| DE202016104106U1 (de) | 2015-08-07 | 2016-10-09 | Hitachi Koki Co., Ltd. | Elektrowerkzeug |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
| AU764371B2 (en) | 1998-08-28 | 2003-08-14 | Eli Lilly And Company | Method for administering insulinotropic peptides |
| US9006175B2 (en) * | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| JP4713798B2 (ja) | 1999-06-29 | 2011-06-29 | マンカインド コーポレイション | ペプチドおよびタンパク質の薬学的因子の精製および安定化 |
| US7464706B2 (en) | 1999-07-23 | 2008-12-16 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
| US7305986B1 (en) | 1999-07-23 | 2007-12-11 | Mannkind Corporation | Unit dose capsules for use in a dry powder inhaler |
| WO2001051071A2 (en) | 2000-01-11 | 2001-07-19 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
| AU2001232735A1 (en) | 2000-01-27 | 2001-08-07 | Eli Lilly And Company | Process for solubilizing glucagon-like peptide 1 compounds |
| US6608038B2 (en) | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| EP1301187B1 (en) * | 2000-07-04 | 2005-07-06 | Novo Nordisk A/S | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
| CN1501809B (zh) | 2000-12-13 | 2012-10-10 | 伊莱利利公司 | 应用胰高血糖素样促胰岛肽的长期治疗方案 |
| JP2005506956A (ja) | 2001-06-01 | 2005-03-10 | イーライ・リリー・アンド・カンパニー | 長時間作用性ｇｌｐ−１製剤 |
| US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
| US20040038865A1 (en) | 2002-08-01 | 2004-02-26 | Mannkind Corporation | Cell transport compositions and uses thereof |
| US20040121964A1 (en) | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| CA2458288A1 (en) * | 2003-03-11 | 2004-09-11 | Institut De Cardiologie De Montreal / Montreal Heart Institute | Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure |
| NZ548980A (en) * | 2004-01-12 | 2009-10-30 | Mannkind Corp | Reducing serum proinsulin levels in type 2 diabetics |
| US20050265927A1 (en) | 2004-05-17 | 2005-12-01 | Yale University | Intranasal delivery of nucleic acid molecules |
| DK1791542T3 (en) | 2004-08-23 | 2015-06-15 | Mannkind Corp | Diketopiperazinsalte for pharmaceutical delivery |
| SE0402976L (sv) | 2004-12-03 | 2006-06-04 | Mederio Ag | Medicinsk produkt |
| EP1827381A1 (en) | 2004-12-03 | 2007-09-05 | Mederio AG | A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation |
| WO2006086107A2 (en) * | 2005-01-10 | 2006-08-17 | Mannkind Corporation | Methods and compositions for minimizing accrual of inhalable insulin in the lungs |
| CA2617226A1 (en) * | 2005-08-01 | 2007-02-08 | Mannkind Corporation | Method of preserving the function of insulin-producing cells |
| KR101486397B1 (ko) | 2005-09-14 | 2015-01-28 | 맨카인드 코포레이션 | 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법 |
| AU2007216966C1 (en) | 2006-02-22 | 2014-03-20 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| WO2007121411A2 (en) | 2006-04-14 | 2007-10-25 | Mannkind Corporation | Glucagon-like peptide 1(glp-1) pharmaceutical formulations |
| KR101736535B1 (ko) * | 2007-10-24 | 2017-05-16 | 맨카인드 코포레이션 | Ｇｌｐ-1에 의한 유해 효과의 예방 방법 |
| AU2008316636B2 (en) | 2007-10-24 | 2014-02-06 | Mannkind Corporation | Delivery of active agents |
-
2010
- 2010-01-08 MX MX2011007371A patent/MX2011007371A/es active IP Right Grant
- 2010-01-08 SI SI201030852T patent/SI2379100T1/sl unknown
- 2010-01-08 WO PCT/US2010/020448 patent/WO2010080964A1/en not_active Ceased
- 2010-01-08 EP EP10700456.6A patent/EP2379100B1/en not_active Not-in-force
- 2010-01-08 ES ES10700456.6T patent/ES2529100T3/es active Active
- 2010-01-08 JP JP2011545442A patent/JP5918539B2/ja not_active Expired - Fee Related
- 2010-01-08 CA CA2749099A patent/CA2749099A1/en not_active Abandoned
- 2010-01-08 EP EP14187552.6A patent/EP2853268A1/en not_active Withdrawn
- 2010-01-08 US US13/257,284 patent/US9078866B2/en active Active
- 2010-01-08 DK DK10700456.6T patent/DK2379100T3/en active
- 2010-01-08 PT PT107004566T patent/PT2379100E/pt unknown
- 2010-01-08 AU AU2010203573A patent/AU2010203573A1/en not_active Abandoned
-
2015
- 2015-03-24 JP JP2015060794A patent/JP2015157817A/ja active Pending
-
2016
- 2016-01-15 AU AU2016200249A patent/AU2016200249A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK2379100T3 (en) | 2014-12-01 |
| AU2010203573A1 (en) | 2011-06-30 |
| HK1164112A1 (en) | 2012-09-21 |
| EP2853268A1 (en) | 2015-04-01 |
| US20120094905A1 (en) | 2012-04-19 |
| SI2379100T1 (sl) | 2015-02-27 |
| AU2016200249A1 (en) | 2016-02-04 |
| EP2379100B1 (en) | 2014-11-12 |
| JP5918539B2 (ja) | 2016-05-18 |
| US9078866B2 (en) | 2015-07-14 |
| JP2012514646A (ja) | 2012-06-28 |
| CA2749099A1 (en) | 2010-07-15 |
| ES2529100T3 (es) | 2015-02-16 |
| EP2379100A1 (en) | 2011-10-26 |
| WO2010080964A1 (en) | 2010-07-15 |
| PT2379100E (pt) | 2015-02-09 |
| JP2015157817A (ja) | 2015-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011007371A (es) | Metodo para tratar la hiperglucemia con la molecula. | |
| Cramer et al. | Effects of yoga on cardiovascular disease risk factors: a systematic review and meta-analysis | |
| MX2007012102A (es) | Control superior de glucosa en la sangre en tratamiento de diabetes. | |
| JP2013541576A5 (es) | ||
| PL2211842T3 (pl) | Preparat suchego proszku do inhalacji zawierający glp-1 do stosowania w leczeniu hiperglikemii i cukrzycy w podawaniu płucnym | |
| WO2007139941A3 (en) | Composition and methods for treatment of congestive heart failure | |
| FI3524261T3 (fi) | Exendin käytettäväksi diabeteksen hoidossa ja ruumiin painon vähentämiseksi | |
| NZ608829A (en) | Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof | |
| JP2011105610A5 (es) | ||
| WO2007076505A3 (en) | Transferrin and transferrin-based compositions for diabetes treatment | |
| SG159462A1 (en) | Multi-herbal medicinal composite for treating the metabolic syndrome and preparation method thereof | |
| England et al. | Efficacy, Safety And Tolerability Of Inhaled Dry Powder Insulin (Exubera®) In Adult Diabetics With Asthma | |
| WO2009057461A1 (ja) | 糖尿病治療剤 | |
| ZHANG | Clinical curative effect of captopril combined with nifedipine sustained-release tablets in the treatment of hypertension in patients with type 2 diabetes | |
| LIU et al. | Effect of glucagon-like peptide-1 analogue combined with insulin for treating obese or overweight type 2 diabetes | |
| LAO et al. | Cinical observation of insulin detemir combined with acarbose in curing type 2 diabetic patients | |
| Agarwal et al. | Study of optimal basal insulin glargine dose requirement in Indian population as an add on therapy to oral hypoglycaemic agents to achieve target fasting blood glucose levels | |
| YAN et al. | Clinical observation on treatment of 52 cases of type 2 diabetes Sangjiao Decoction | |
| Safy et al. | Glycemic control in adolescents with insulin-dependent diabetes IDD: comprehensive guidelines for diabetes self-management | |
| YE et al. | Observation of the curative effect of insulin human analog in the application on diabetic patients during perioperative period | |
| ZHANG et al. | Efficacy of continuous glucose monitoring system combined with insulin pump in diabetic pafients aged 60 years and over | |
| Sukhinina et al. | Effektivnost'ispol'zovaniya interval'noy gipoksicheskoy trenirovki v sochetanii s apparatnymtraktsionnym metodom v reabilitatsionnoy programme patsientov s degenerativno-distroficheskimizabolevaniyami pozvonochnika | |
| Abdulmohsen et al. | Current practice in the management of patients with type 2 diabetes mellitus in Saudi Arabia | |
| HOU et al. | Clinical observation of exenatide for treatment of obesity type 2 diabetes mellitus complicated with obstructive sleep apnea hypopnea syndrome | |
| Samaria et al. | Mechanical Ventilation and In-Hospital Mortality in Patients of Acute Exacerbation of COPD (AECOPD) on Conventional Treatment Versus Non Invasive Positive Airway Pressure (NIPPV). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |